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Abstract
BMI-1 is overexpressed in a variety of cancers, which can elicit an immune response leading to the induction of
autoantibodies. However, BMI-1 autoantibody as a biomarker has seldom been studied with the exception of
nasopharyngeal carcinoma. Whether BMI-1 autoantibodies can be used as a biomarker for cervical carcinoma is unclear.
In this study,BMI-1 proteins were isolated by screening of a T7 phage cDNA library from mixed cervical carcinoma tissues.
We analyzed BMI-1 autoantibody levels in serum samples from 67 patients with cervical carcinoma and 65 controls using
ELISA and immunoblot. BMI-1 mRNA or protein levels were over-expressed in cervical carcinoma cell lines. Immunoblot
results exhibited increased BMI-1 autoantibody levels in patient sera compared to normal sera. Additionally, the results for
antibody affinity assay showed that there was no difference between cervical polyps and normal sera of BMI-1 autoantibody
levels, but it was significantly greater in patient sera than that in normal controls (patient 0.82760.043 and normal
0.44560.023; P,0.001). What’s more, the levels of BMI-1 autoantibody increased significantly at stage I (0.67260.019)
compared to normal sera (P,0.001), and levels of BMI-1 autoantibodies were increased gradually during the tumor
progression (stage I 0.67260.019; stage II 0.775 60.019; stage III 0.890 60.027; stage IV 1.04360.041), which were
significantly correlated with disease progression of cervical carcer (P,0.001). Statistical analyses using logistic regression
and receiver operating characteristics (ROC) curves indicated that the BMI-1 autoantibody level can be used as a biomarker
for cervical carcinoma (sensitivity 0.78 and specificity 0.76; AUC=0.922). In conclusion, measuring BMI-1 autoantibody levels
of patients with cervical cancer could have clinical prognostic value as well as a non-tissue specific biomarker for neoplasms
expressing BMI-1.
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Introduction
Cervical cancanoma is much more deadly in developing
countries than in developed countries [1]. Cervical cancer
incidence rates have decreased significantly in developed coun-
tries, largely due to the early diagnosis of precancerous lesions and
early treatment following detection [2]. Due to the relative
inefficiency of cervical screening in developing countries, the
incidence of cervical cancer was six times as high as that in
developed countries [3]. Screening is the basic practice in cancer
prevention for cervical cancer [4]. There are several alternative
techniques for screening for pre-cancerous lesions for cervical
cancer, including the Pap smear, visual inspection with acetic acid
(VIA), human papilloma virus (HPV) DNA testing and combined
Pap smear and VIA [3,4]. As cervical cytology screening has
become more prevalent, preinvasive lesions of the cervix are
detected far more frequently than invasive cancers. Early detection
can make a significant difference for the treatment outcome of
cervical cancer [1]. HPV testing is more sensitive, but less specific
than conventional cytology for detecting high-grade cervical
intraepithelial neoplasia (CIN) [5]. HPV testing is less specific
than cytology because many infections regress without developing
high-grade lesions [6,7]. There is therefore a need to identify
strategies for increasing specificity with HPV DNA testing while
maintaining its advantage in terms of sensitivity.
BMI-1 is a transcriptional repressor, which belongs to the
polycomb group family [8] and was originally identified as an
oncogene that cooperates with c-myc in the oncogenesis of mouse
lymphomas. BMI-1-deficient mouse embryonic fibroblasts (MEF)
overexpress INK4a/ARF locus–encoded genes, p16INK4a and
p19ARF (mouse homologue of human p14ARF) and undergo
premature senescence in culture [9,10]. Proper function of this
family is maintaining gene expression patterns during develop-
ment. This gene plays a key role in the self-renewal of stem cells. It
has been demonstrated that over-expression of BMI-1 occurs in a
variety of cancers [11,12,13], including several types of leukemia
and solid tumors such as non–small cell lung cancer, mantle cell
lymphomas, colorectal cancer and prostate cancer suggesting a
role in tumor cell growth and survival. Recently, BMI-1 over-
expression has been identified as a marker of poor prognosis and
metastasis in breast cancer, acute myeloid leukemia and
neuroblastoma. Notably, BMI-1 is associated with both humoral
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e27804and T-cell responses, suggesting that it represents a novel family of
tumor-associated antigens (TAAs) that might be potential target
for immunotherapy [14,15].
New biomarkers, such as autoantibody signatures, may improve
the early detection of cervical carcinoma. Therefore,in this study,
we employed efficient methodologies to determine levels of BMI-1
autoantibodies in patient sera from a cDNA T7 phage display
library constructed with mixed cervical carcinoma tissues. The
immunogenic BMI-1 protein expression in recombinant phage
was detected through immunochemistry and ELISA. We further




Cervical carcinoma cell lines (including HeLa, Caski and SiHa),
and normal cervical cell line H8 were cultured in RPMI 1640
medium supplemented with 10% fetal bovine serum and
antibiotics (100 U streptomycin/100 U penicillin) in a humidified
atmosphere at 37uC with 5% CO2. BMI-1 positive cell line K562
derived from chronic myeloid leukemia (CML) was used for
control. All cell lines were obtained from China Center for Type
Culture Collection, Wuhan University.
Ethics statement
The study was approved by the Medical Ethics Review
Committee of Renmin Hospital, Wuhan University. All partici-
pants in this study were required to provide a written informed
consent in accordance with Renmin Hospital of Wuhan University
Ethics Committee; patients under supervision of a lawful caregiver
if necessary.
Patients and Sera Preparations
Following informed consent, a total of 77 samples of peri-
pheral blood was obtained from individuals with histologically
confirmed cervical carcinomas prior to treatment at the
Department of Gynaecology and Obstetrics, Renmin Hospital,
Wuhan University. 52 samples of peripheral blood obtained
from individuals with chronic cervicits, and 39 samples of
peripheral blood from individuals with CIN. 73 samples of
normal sera were obtained from healthy blood donors. The
majority of patients were stage (stages I: n=25; stages II: n=23;
stages III: n=18; stage IV: n=11). Cervical carcimoma was
biopsy-proven in all squamous cell carcinoma types. Their ages
ranged from 21 to 76 years, with a median age of 53 years.
Clinicopathological parameters, such as the depth of tumor
invasion, lymphatic and venous involvement, and regional
lymph node metastasis were evaluated according to the
International Federation of Gynecology and Obstetrics (FIGO)
recommendation [16]. All samples were centrifugated for 5 min
at 3000 g, and then frozen and stored at -80uC. Ten cervical
carcinoma sera and 8 normal sera were used to biopan, and 67
cervical carcinoma samples (Table1) and 65 normal samples, not
including the sera used to biopan, were used to evaluate
predictive value by ROC curves.
RNA extraction and Reverse transcription-PCR (RT-PCR)
Total RNA was isolated from the cells by the acid guanidinium
thiocyanate-phenol-chloroform method using a Trizol reagent
(MBI Fermentas, Lithuania) according to the manufacturer’s
instructions. The RNA was treated with DNase, and 2.5mg of total
RNA was utilized for cDNA synthesis using random hexamers
(MBI Fermentas, Lithuania). Full-length open reading frame of
BMI-1 was amplified by PCR from cDNA samples of cervical
carcinoma cell lines. The following primers were used for
amplification of BMI-1: sense primer, 59-ACCTGATGTGTGT-
GCTTTGTG-39; antisense primer, 59-TGCTGGGCATCG-
TAAGTATCT-39. The primers used for glyceraldehyde-3-
phosphate dehydrogenase (GADPH, internal control) were 59-
AATCCCATCACCATCTTCCA-39 and 59-CCTGCTTCAC-
CACCTTCTTG-39. The PCR products were analyzed by
agarose gel electrophoresis and confirmed by appropriate size
and/or sequencing.
Protein extraction and Western blot
Cells were washed with PBS and lysed on ice with cold RIPA
buffer (Sigma-Aldrich, Steinheim, Germany) containing protease
inhibitors (Complete Mini, Roche Diagnostics, Mannheim,
Germany). Whole cell protein extracts were separated on 10%
SDS-PAGE and electroblotted onto a nitrocellulose membrane
(Amersham). The blocked membrane was incubated first with
cervical carcinoma patient serum or Anti-b-actin antibody (Santa
Cruz Biotechnology, Inc) and then with goat anti-human
antibody conjugated with horseradish peroxidase (Promega).
The signal was detected using Pierce ECL Western Blotting
Substrate.
Immunodetection to define differences in antibody
reactivity of normal and cervical carcinoma patient serum
Using preferential affinity of antibodies found in cervical
carcinoma patient sera and not in normal sera, BMI-1-expressing
phages were isolated from a mixture cervical carcinoma tissues T7
phage cDNA library. Isolated phages expressing BMI-1 was
plaqued to limiting dilution on LB-Agar/agarose plates. Individual
protein-expressing phages were plaqued to limiting dilution on
LB-Agar/agarose plates and then lifted onto a nitrocellulose
membrane for immunodetection as above. The plaque-lifted
membranes were cut into several strips and blocked with 5%
blocking reagent in 16TBST. The individual strips were
incubated with serum from individual cervical carcinoma patients
or pooled normal sera (1:100) that were not used in the biopan
procedure. Next, the strips were incubated with anti-human HRP-
Table 1. Clinical and Pathological Information for Cervical
Carcinoma Patients for ELISA.
Category Subcategory No. of patients
Age(years) 5165.8
Tumor size #4cm 35
.4cm 32








Distant metastasis Negative 51
Positive 16
doi:10.1371/journal.pone.0027804.t001
BMI-1 Antoantibody for Cervical Carcinoma
PLoS ONE | www.plosone.org 2 November 2011 | Volume 6 | Issue 11 | e27804conjugated secondary Ab and detected with DAB staining as
previously described [17].
Enzyme-linked immunosorbent assay for antibodies
against BMI-1
ELISAs were developed for the phage-expressed proteins to
confirm their immunogenic reactivity with different patient serum.
96-well microtiter plates (Costar, Corning, USA) were coated with
PEG-purified phages expressing BMI-1 or empty phages as a
negative control (10
9 phage/well in 16PBS/1% BSA at 4uC,
overnight), then blocked (PBS/BSA 37uC, 1h) and washed (PBS/
Tween 20). Serially diluted (1:20 to 1:2560) serum samples from
individual patients that were not used in the biopan were added to
each well (37uC, 1h). The plates were washed (3 times, 5 min/
time), and then incubated with anti-human HRP secondary Ab
(37uC, 1h). Assays were developed with 2, 29-azino-bis-(3-
ethylbenzothiazoline-6-sulfonic acid) (ABTS)/H2O2 substrate
(Sigma, German) for 20 min, and then read on a spectrophotom-
eter at 405nm. Each individual serum was run in triplicate. In
separated experiments sera were assayed at a single dilution
(1:100) and absorbance was used as a measure of antibody
reactivity in each independent assay. 65 normal serum samples
and 40 patient samples were assessed for antibodies to the phages
expressing BMI-1. The data were analyzed for each marker and
combinations of two or more markers.
Statistical analysis
Results were expressed as mean 6 Standard deviation (SD).
Associations between different variables were assessed by the
Mann–Whitney test and one-way analysis of variance (ANOVA)
was used to compare continuous variables among the groups.
Logistic regression was used to determine whether a sample was
from a cervical carcinoma or a healthy donor. A model was
constructed using BMI-1 autoantibody measurements as explan-
atory variable. Receiver operating characteristics (ROC) curves
was used to evaluate the sensitivity and specificity for predicting
cervical carcinoma. Statistical analysis was carried out using SPSS
software, version 13.0 (SPSS Inc., Chicago,IL, USA). A P value
less than 0.05 was considered statistically significant. All data were
analyzed anonymously.
Results
The expression of BMI-1 levels in cervical carcinoma cell
lines
We analyzed the expression of BMI-1 in several human cervical
carcinoma cell lines using RT-PCR or Western blot. BMI-1 was
expressed at different degree compared with the expression of
control cell line (Fig.1A and 1C). The ratio of BMI-1 expression in
cervical carcinoma cell lines was singnificantly increased in all of
the three cervical carcinoma cell lines compare to that in H8 cell
line (Fig.1B and 1D) (P,0.05).
BMI-1 phage from a T7 phage cDNA library of mixed
cervical carcinoma tissues reacted with patient’s sera
Following a series of sequential selection and enrichment steps,
we isolated phages that had high immunochemical reactivity with
patient sera. After PCR amplification and sequencing, by
Figure 1. The expression of BMI-1 in cervical carcinoma cell lines and controls. A. RT-PCR analysis of BMI-1 mRNA in various cervical
carcinoma cell lines. B. The ratio of BMI-1 mRNA expression in various cervical carcinoma cell lines. C. Immunoblotting of BMI-1 protein in various
cervical carcinoma cell lines. D. Quantification of BMI-1 protein expression in various cervical carcinoma cell lines. The cervical carcinoma cell lines
included HeLa, Caski, and SiHa. K562 was used as a positive control. H8 was a normal cervical cell line. GAPDH was used as an internal control.
doi:10.1371/journal.pone.0027804.g001
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performed by DAB to define differences in antibody reactivity between normal and cervical carcinoma patient serum. T7 phage expressing BMI-1 was
plated on LB-Agar and plaque lifted onto nitrocellulose membrane that was then cut into strips. Strips were incubated with pooled cervical
carcinoma patient sera or normal sera followed by incubation with anti-human secondary antibodies. The sera were those used in the initial
biopanning. Spots represent individual phage colonies. Comparisons between normal and cervical carcinoma sera for BMI-1 phage were shown.
doi:10.1371/journal.pone.0027804.g002
Figure 3. ELISA of phage-expressing BMI-1 proteins with individual serum samples. The assays were performed with serially diluted (1:20
to 1:2560) individual serum samples that were not used in the biopan to confirm that measurements were representative of an antigen-antibody
affinity reaction. Representative curves from four patients (P1, P2, P3, P4, P5) are shown for each protein. Measurements are expressed as mean
absorbance minus the value of each serum sample assayed against empty T7 phage (background) 6 SEM absorbance. Data from empty T7 phage at
each dilution, for each patient sample, are shown as a reference.
doi:10.1371/journal.pone.0027804.g003
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identified BMI-1 from T7 cDNA phage library of mixed cervical
carcinoma tissues. Relative specificity for this protein using this
approach was confirmed by the comparison of immunochemical
reactivity of normal and cervical carcinoma patient sera (Fig.2).
Antibody affinity for phage-expressing protein
To confirm antibody affinity in individual serum samples for
specific protein, serum was assayed in limiting dilution from 1:20
to 1:2560 by ELISA constructed with phages BMI-1 and empty
phages as control. Absorbance values for the antibody in sera of
three patients decreased over serial dilutions, suggesting antibody
affinity for BMI-1 protein (Fig.3A). Empty phage controls
exhibited background signals similar to negative controls in each
ELISA (Fig.3B).
ELISA for antibodies against phage-expressing protein
Sera from 65 normal and 67 cervical carcinoma patients were
then evaluated to establish relative ranges for BMI-1 antibodies.
The average of BMI-1 antibody absorbance values were
significantly elevated above the mean of normal sera
(0.57060.0128 versus 0.80160.019; P,0.001), and there were
no significant differences between normal sera and the sera of
chronic cervitics (0.57660.013) and CIN (0.58060.016) (Fig.4A).
Logistic regression was used to estimate the probability of a serum
sample from a cervical carcinoma patient. Based on our data, it
seems that such a model when using BMI-1 autoantibody
measurements as an explanatory variable is highly reliable
(P,0.0001). The ROC curve has a c-statistic (i.e. area under the
curve or AUC-ROC) of 0.9224 with an optimal predictive
accuracy of sensitivity 0.78 and specificity 0.76. (Fig.4B).
Correlation of levels of autoantibodies with clinical
progression
We further analyzed the relationship between BMI-1 autoan-
tibody levels and clinical characteristics of patients. levels of BMI-1
autoantibodies were 0.57060.013 in normal sera and
0.50260.020 in cervical polyps, showing that there was no
Figure 4. Comparative measurements of BMI-1 autoantibody in normal and cervical carcinoma sera. A. Box plots of measurement
results of BMI-1 antibody for 65 normal and 67 cervical carcinoma patient sera using Elisa. Mean is shown by horizontal bar inside the box and the
two horizontal bars above and below the box corresponding to mean 6 2 SD. The observations that fall outside 2 SD. from the mean are also shown
in each plot. Mean 6 SEM. for each are as follows: BMI-1: normal 0.57060.013, cancer: 0.80160.019; Values are expressed as absorbance. B. Data from
quantitative ELISA for BMI-1 were evaluated for ability to predict disease. The lower black curve represents the predictive accuracy using the logistic
regression model with BMI-1 ELISA data from 67 patients and 65 normal controls. The upper gray curve represents the predictive accuracy with BMI-1
as explanatory variable where P,0.0001 with c statistic 0.9224.
doi:10.1371/journal.pone.0027804.g004
Figure 5. Measurement of levels of BMI-1 autoantibodies in
normal, nasal polyp and cervical carcinoma sera. Plots of levels
of autoantibodies from the sera of 65 healthy donors and 67 cervical
carcinoma patients measured through Elisa. Mean is shown by the
horizontal bar inside the box and the two horizontal bars above and
below the box represent 62SD. The observations that fall outside 2SD
from the mean are also shown in each plot. Values are expressed as
absorbance.
doi:10.1371/journal.pone.0027804.g005
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increased significantly at stage I (0.67260.019) compared to
cervical polyps or normal sera (P,0.001). Moreover, the level of
BMI-1 autoantibody kept increasing from stage I to stage IV, and
the level of BMI-1 autoantibody was 0.67260.019, 0.77560.019,
0.89060.027 and 1.04360.041, respectively. Taken together, there
was a significant correlation between BMI-1 autoantibody levels
and clinical stages in cervical carcinoma group (P,0.001) (Fig.5).
Discussion
Despite the decrease in cervical cancer incidence due to
improved diagnostic techniques and treatments, there is still a
high mortality rate [2,18]. A number of studies indicate that one or
more oncogenic types of HPV may be responsible for cervical
cancer, which is supported by strong epidemiological evidence and
the detection of HPV DNA in 90–100% of cervical cancers [19].
HPV 16 and 18 are detected in 57.4% and 16.6%, respectively, of
cervical tumor specimens [20,21,22,23]. However, molecular
mechanisms underlying the development and progression of
cervical cancer remain poorly understood.
Currently, polycomb group (PcG) genes, which are pivotal in
regulating gene expression through promoting chromatin modi-
fications, have been deregulated in various human cancers
[24,25]. Therefore, deregulation of mammalian PcG members
may contribute to human carcinogenesis. The transcription of two
tumor suppressors, p16INK4a and p14ARF, human telomerase
reverse transcriptase (h-TERT), as well as oncoprotein c-Myc,
which have been implicated in the regulation of the cell cycle and
proliferation, was found to be mediated by PcG proteins, mainly
BMI-1, in vivo and in vitro. The BMI-1 was a known suppressor of
p16 [26,27]. The overexpression of p16 has been shown to be
associated with progression to CIN3 or cervical carcinoma. HPV-
positive women were also positive for p16 overexpression in
cervical carcinoma [13]. Given the role of PcG proteins in
epigenetic modification, it is possible that abnormal expression of
PcG proteins contributes to the formation of cancer-specific
cellular characteristics [28]. Recently, BMI-1, a member of the
PcG group, has been found to be over-expressed in a variety of
human cancers, including human cervical carcinoma [25,29,30]
resulting in the induction of auto-antibodies that our studies
indicate may be clinical useful. However, there was no evidence to
show that the BMI-1 autoantibody exists in cervical carcinoma.
In our study, we identified BMI-1 from a T7 phage cDNA library
of mixed cervical carcinoma tissues. Using ELISA and immunode-
tection approaches, we demonstrate for the first time that BMI-1
mRNA was over-expressed at different levels in cervical carcinoma
cell lines. Moreover, antibody affinity assay using sera from 67
cervicalcarcinomapatientsand65controlsshowedthat the amount
of BMI-1 antibody was significantly greater in patient sera than in
normal controls (P,0.001). Levels of BMI-1 autoantibody werealso
significantly correlated with disease progression (P=0.001), sug-
gesting that BMI-1 could be a new candidate for screening test in
cervical cancer. We further analyzed our results using logistic
regression and ROC curve, which showed that the BMI-1
autoantibody as potential biomarker for cervical carcinoma has
similar sensitivity and specificity to BMI-1. Although, the defined c-
statistic or areaunder the ROCcurve (AUC-ROC) of 0.9224 in our
series indicates that the predictive value of BMI-1 autoantibody in
cervical carcinoma is modest, cervical carcinoma heterogeneity
showed similar limitations for other cervical carcinoma markers,
such as CYFRA21.1, SCC and CEA, each varying somewhat with
stage and histology [31,32].
Over the years, numerous studies have revealed that the most
probable order of events leading to cervical cancer formation is
from normal cervical mucosa including acquisition of HPV
infection, chronic cervicitis, followed by CIN [33,34]. During
such processes, a series of genetic mutations and deregulation in
cellular homeostasis increase the likelihood of uncontrolled cell
growth and malignancy [35]. However, in the present study, we
did not admit CIN subjects and failed to compare the different
expression in CIN patients and cervical cancer suffers, which
would be our further experimental work.
In conclusion, we highlight the significance of BMI-1 autoan-
tibody in cervical cancer. We showed that patients exhibiting
higher BMI-1 autoantibody levels are associated with cervical
carcinoma progression. Hence, detection of BMI-1 autoantibody
levels may be of great clinical value to screen those with high risk
of cervical cancer and BMI-1 autoantibody status may be useful to
stratify patients for novel therapeutic strategies.
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